KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Gains from Sales and Divestitures: 2011-2017

  • Idexx Laboratories' Gains from Sales and Divestitures fell 8.82% to $155,000 in Q4 2017 from the same period last year, while for Dec 2017 it was $155,000, marking a year-over-year decrease of 8.82%. This contributed to the annual value of $155,000 for FY2017, which is 8.82% down from last year.
  • As of Q4 2017, Idexx Laboratories' Gains from Sales and Divestitures stood at $155,000, which was down 8.82% from $170,000 recorded in Q4 2016.
  • Idexx Laboratories' 5-year Gains from Sales and Divestitures high stood at $170,000 for Q4 2016, and its period low was $122,000 during Q4 2014.
  • For the 2-year period, Idexx Laboratories' Gains from Sales and Divestitures averaged around $162,500, with its median value being $162,500 (2016).
  • Data for Idexx Laboratories' Gains from Sales and Divestitures shows a maximum YoY dropped of 12.23% (in 2014) over the last 5 years.
  • Quarterly analysis of 4 years shows Idexx Laboratories' Gains from Sales and Divestitures stood at $139,000 in 2013, then declined by 12.23% to $122,000 in 2014, then reached $170,000 in 2016, then dropped by 8.82% to $155,000 in 2017.
  • Its Gains from Sales and Divestitures was $155,000 in Q4 2017, compared to $170,000 in Q4 2016 and $122,000 in Q4 2014.